# Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease

Study · id `cardio:ct-nct06930885` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06930885](<https://clinicaltrials.gov/study/NCT06930885>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06930885

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 7713 participants.

## Technical summary

Registry record NCT06930885. Randomized; quadruple masking; primary purpose treatment. Start 2025-06-12 (actual); primary completion 2031-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 7713 participants (planned count; ClinicalTrials.gov record NCT06930885, source copy `cardio:ctgov-nct06930885-2026-01-22`, retrieved 2026-10-31)
- Started: 2025-06-12 (actual) (ClinicalTrials.gov record NCT06930885, source copy `cardio:ctgov-nct06930885-2026-01-22`, retrieved 2026-10-31)
- Primary completion: 2031-05 (anticipated) (ClinicalTrials.gov record NCT06930885, source copy `cardio:ctgov-nct06930885-2026-01-22`, retrieved 2026-10-31)
- Completion: 2031-05 (anticipated) (ClinicalTrials.gov record NCT06930885, source copy `cardio:ctgov-nct06930885-2026-01-22`, retrieved 2026-10-31)
- Countries: Brazil (ClinicalTrials.gov record NCT06930885, source copy `cardio:ctgov-nct06930885-2026-01-22`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06930885-2026-01-22`, retrieved 2026-10-31)

## The registry's words

- Brief title: Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease
- Acronym: EPOCA
- Condition: Atherothrombotic Diseases
- Condition: Atherosclerotic Cardiovascular Disease (ASCVD)
- Intervention (Drug): Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin)
- Intervention (Drug): Colchicine 0.5 mg
- Intervention (Drug): Usual Care Group
- Intervention (Drug): Colchicine-placebo 0.5 mg
- Lead sponsor: Hospital do Coracao
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: Hospital do Coracao (`cardio:org-hospital-do-coracao`)

## Provenance

Content hash: ff81930827baa28d5eb4f8bacfc3985ce73f8f82a8ccecd0f7c82960ae4be1c3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
